2-苯基噻唑-4-甲酸乙酯 | 59937-01-8

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-苯基噻唑-4-甲酸乙酯
• 中文别名: 2-苯基-4-噻唑羧酸乙酯
• 英文名称: ethyl 2-phenylthiazole-4-carboxylate
• 英文别名: 2-phenyl-4-carbethoxythiazole；2-phenylthiazole-4-carboxylic acid ethyl ester；Ethyl 2-phenyl-1,3-thiazole-4-carboxylate
• CAS: 59937-01-8
• 化学式: C₁₂H₁₁NO₂S
• mdl: MFCD06205115
• 分子量: 233.291
• InChiKey: UKKGDCGESAFSJY-UHFFFAOYSA-N

物化性质

• 熔点：
  47 °C
• 沸点：
  365℃
• 密度：
  1.216
• 闪点：
  175℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934100090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温、避光、干燥密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 2-phenyl-1,3-thiazole-4-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 2-phenyl-1,3-thiazole-4-carboxylate
CAS number: 59937-01-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H11NO2S
Molecular weight: 233.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苯基噻唑-4-甲酸乙酯 在 甲醇 、 sodium tetrahydroborate 、 草酰氯 、 水 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 二丁醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.81h， 生成 1-(2-phenylthiazol-4-yl)ethanol
  参考文献：
  名称：

  [EN] IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
  [FR] DÉRIVÉS D'IMIDAZOTHIADIAZOLE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DU RÉCEPTEUR 4 ACTIVÉ PAR UNE PROTÉASE (PAR4) POUR LE TRAITEMENT DE L'AGRÉGATION PLAQUETTAIRE

  摘要：

  本发明提供了式I的噻唑化合物，其中W、Y、R0、R2、R4、R5、R6、R7、X1、X2、X3和X4如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药酯或溶剂化合物形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。

  公开号：

  WO2013163279A1
• 作为产物：
  描述：

  马尿酸乙酯 在 劳森试剂 、 18-冠醚-6 、 sodium hydride 作用下， 以 1,4-二氧六环 、 甲苯 为溶剂， 反应 12.0h， 生成 2-苯基噻唑-4-甲酸乙酯
  参考文献：
  名称：

  使用C-甲酰化策略从常见的无环前体合成咪唑，恶唑，噻唑和2,5-二羧酸吡嗪二乙酯的取代酯

  摘要：

  报道了一种通过甘氨酸乙酯盐酸盐的C-甲酰化反应合成咪唑，恶唑，噻唑和吡嗪-2,5-二羧酸二乙酯的取代酯的新颖合成途径。该方法简单，稳健，并且可以在一个或两个步骤中从常见的无环前体中很好地获得不同杂环酯的收率，并且适合大规模合成。

  DOI：

  10.1016/j.tetlet.2014.03.039

文献信息

• Design, synthesis and Structure–activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
  作者：Zheng Li、Qianqian Qiu、Xue Xu、Xuekun Wang、Lei Jiao、Xin Su、Miaobo Pan、Wenlong Huang、Hai Qian

  DOI：10.1016/j.ejmech.2016.02.040

  日期：2016.5

  The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of

  游离脂肪酸受体1（FFA1 / GPR40）作为治疗2型糖尿病的新靶标已引起人们的关注。相对较高的分子量和亲脂性阻碍了包括FAK1激动剂在内的数个系列的FFA1激动剂（由于对肝毒性的担忧而在III期研究中终止的最先进的化合物）。为了通过降低亲脂性来开发具有低肝毒性风险的有效FFA1激动剂，TAK-875的中间苯基被11个极性五元杂芳族化合物所取代。随后，对SAR的系统探索和分子建模的应用导致了化合物44的鉴定，它是一种出色的FFA1激动剂，在正常和2型糖尿病小鼠中均具有强大的降血糖作用，即使在两倍摩尔的TAK-875剂量下也具有低血糖风险和肝毒性。同时，指出了两个重要发现。首先，我们的噻唑系列中的甲基占据了一个小的疏水亚口袋，与TAK-875没有相互作用。此外，激动活性显示与噻唑核心和末端苯环之间的二面角具有良好的相关性。这些结果促进了对配体结合口袋的了解，并可能有助于设计更有希望的FFA1激动剂。
• [EN] INHIBITORS OF HUMAN ATGL<br/>[FR] INHIBITEURS DE L'ATGL HUMAIN
  申请人：KARL FRANZENS UNIV GRAZ

  公开号：WO2021019051A1

  公开（公告）日：2021-02-04

  The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.

  本发明涉及新型抑制脂肪甘油三酯脂肪酶（ATGL）的抑制剂，其对人类ATGL（hATGL）具有改善的抑制活性，以及包含这些抑制剂的药物组合物，及其治疗用途，特别是在治疗或预防脂质代谢紊乱方面的用途，包括例如肥胖、非酒精性脂肪肝病、2型糖尿病、胰岛素抵抗、葡萄糖不耐症、高甘油三酯血症、代谢综合征、心脏和骨骼肌脂肪变性、先天性全身性脂肪营养不良、家族性部分脂肪营养不良、获得性脂肪营养不良综合征、动脉粥样硬化或心力衰竭。
• Bleomycin analogs. Phenylthiazole models of the bithiazole moiety of bleomycin A2
  作者：James M. Riordan、Ted T. Sakai

  DOI：10.1021/jm00360a018

  日期：1983.6

  analogues was further indicated by viscometric measurements using calf thymus DNA. The data show that a phenyl ring allows the aromatic systems to interact with the base pairs of the polynucleotide to a greater extent than a thiazole ring in the same position. Possible models for the interaction of these derivatives with DNA are considered. The hydrogens of the biphenyl derivative show an interaction

  含有博来霉素A2的（3-氨基丙基）二甲基s氯化物侧链的2-苯基噻唑-4-羧酸，2'-苯基-2,4'-噻唑-4-羧酸和4,4'-联苯基羧酸的酰胺具有制备了它们，并通过质子核磁共振光谱研究了它们与聚（dA-dT）的结合。苯基噻唑和苯基噻唑衍生物在多核苷酸的存在下均表现出氢的高场位移，这比先前研究的类似的完全杂环系统中观察到的位移大得多（Sakai，TT； Riordan，JM； Glickson，JD Biochemistry 1982， 21，805）。这些类似物结合的插入性质通过使用小牛胸腺DNA的粘度测定进一步表明。数据表明，与噻唑环在相同位置相比，苯环允许芳族系统与多核苷酸的碱基对相互作用的程度更大。考虑了这些衍生物与DNA相互作用的可能模型。联苯衍生物的氢原子之间的相互作用显着小于在含杂环的系统中观察到的相互作用，这表明环系统取向不正确或环系统是非平面的。相似的苯基（苯甲酰基）化合物
• Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family
  作者：Lincheng Fang、Zhaoxue Hu、Yifei Yang、Pan Chen、Jinpei Zhou、Huibin Zhang

  DOI：10.1016/j.bmc.2021.116133

  日期：2021.6

  Bromodomain and extra-terminal (BET) is a promising therapeutic target for various hematologic cancers. We used the BRD4 inhibitor compound 13 as a lead compound to develop a variety of compounds, and we introduced diverse groups into the position of the compound 13 orienting toward the ZA channel. A series of compounds (14–23, 38–41, 43, 47–49) bearing triazolopyridazine motif exhibited remarkable

  Bromodomain and extra-terminal (BET) 是各种血液癌症的有希望的治疗靶点。我们使用BRD4抑制剂化合物13作为先导化合物开发了多种化合物，我们在化合物13朝向ZA通道的位置引入了不同的基团。的一系列化合物的（14-23，38-41，43，47-49）轴承三唑并哒嗪基序表现出显着的BRD4蛋白抑制活性。其中，化合物39抑制BRD4(BD1)蛋白的IC 50为0.003 μM，优于先导化合物13。同时，化合物39具有 抗 U266 癌细胞的抗增殖活性，IC 50 = 2.1 μM。另一方面，化合物39可以阻止肿瘤细胞进入G0/G1期并诱导细胞凋亡，这与其抑制细胞增殖的结果一致。生物学和生化数据表明，BRD4 蛋白可能是一个治疗靶点，而化合物39是进一步开发的极好先导化合物。
• [EN] SHMT INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE SHMT ET LEURS UTILISATIONS
  申请人：RAZE THERAPEUTICS INC

  公开号：WO2018106636A1

  公开（公告）日：2018-06-14

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。